BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)

NCT ID: NCT00605215

Last Updated: 2022-04-21

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 1331 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-04-24
• Study Completion Date: 2011-06-10

Brief Summary

The study aims to compare the effect of daily oral treatment of laquinimod capsules 0.6 milligrams (mg) with the effect of placebo capsules (capsules that contain no active medication) as well as with the effect of an existing Multiple Sclerosis (MS) injectable drug: Interferon β-1a (Avonex®).

Conditions

Multiple Sclerosis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Placebo

Participants will receive 1 capsule of placebo matching to laquinimod orally once daily for 24 months.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo matching to laquinimod will be administered per schedule specified in the arm description.

Laquinimod

Participants will receive 1 capsule of laquinimod 0.6 mg orally once daily for 24 months.

Group Type: EXPERIMENTAL

Laquinimod

Intervention Type: DRUG

Laquinimod will be administered per dose and schedule specified in the arm description.

Avonex®

Participants will receive an injection of Avonex® 30 micrograms (mcg) given intramuscularly (IM) once weekly for 24 months.

Group Type: ACTIVE_COMPARATOR

Avonex®

Intervention Type: DRUG

Avonex® will be administered per dose and schedule specified in the arm description.

Interventions

Laquinimod

Laquinimod will be administered per dose and schedule specified in the arm description.

Intervention Type: DRUG

Placebo

Placebo matching to laquinimod will be administered per schedule specified in the arm description.

Intervention Type: DRUG

Avonex®

Avonex® will be administered per dose and schedule specified in the arm description.

Intervention Type: DRUG

Other Intervention Names

Interferon β-1a

Eligibility Criteria

Inclusion Criteria

1. Subjects must have a confirmed and documented MS diagnosis as defined by the Revised McDonald criteria [Ann Neurol 2005: 58:840-846], with a relapsing-remitting disease course.

2. Subjects must be ambulatory with converted Kurtzke EDSS score of 0-5.5.

3. Subjects must be in a stable neurological condition between screening (month -1) and baseline visits (month 0).

4. Subjects must have had experienced one of the following:

5. At least one documented relapse in the 12 months prior to screening

6. At least two documented relapses in the 24 months prior to screening

7. One documented relapse between 12 and 24 months prior to screening with at least one documented T1-Gd enhancing lesion in an MRI performed within 12 months prior to screening.

8. Subjects must be between 18 and 55 years of age, inclusive.

9. Subjects must have disease duration of at least 6 months (from first symptom) prior to screening.

10. Women of child-bearing potential must practice 2 acceptable methods of birth control [acceptable methods of birth control in this study include: surgical sterilization, intrauterine devices, oral contraceptive, contraceptive patch, long-acting injectable contraceptive, partner's vasectomy or double-barrier method (condom or diaphragm with spermicide)].

11. Subjects must be willing and able to comply with the protocol requirements for the duration of the study.

Exclusion Criteria

1. An onset of relapse or any treatment with corticosteroids (intravenous [iv], intramuscular [im] and/or per os [po]) or ACTH between month -1 (screening) and 0 (baseline).

2. Use of experimental or investigational drugs, and/or participation in drug clinical studies within the 6 months prior to screening.

3. Use of immunosuppressive (including Mitoxantrone (Novantrone®) or cytotoxic agents within 6 months prior to the screening visit.

4. Previous use of either of the following: natalizumab (Tysabri®), cladribine or laquinimod.

5. Previous treatment with glatiramer acetate (Copaxone®) or IVIG within 3 months prior to screening visit.

6. Previous treatment with Interferon beta-1a (Avonex® or Rebif®) or Interferon beta-1b (Betaseron®).

7. Systemic corticosteroid treatment of ≥30 consecutive days duration within 2 months prior to screening visit.

8. Previous total body irradiation or total lymphoid irradiation.

9. Previous stem-cell treatment, autologous bone marrow transplantation or allogenic bone marrow transplantation.

10. A known history of tuberculosis.

11. Acute infection 2 weeks prior to baseline visit.

12. Major trauma or surgery 2 weeks prior to baseline visit.

13. A history of vascular thrombosis (excluding catheter-site superficial venous thrombophlebitis).

14. A carrier state of factor V Leiden mutation (either homo- or heterozygous) by history or as disclosed at screening.

15. Positive screening test for Hepatitis B surface antigen, Hepatitis C antibody, or HIV antibody as disclosed at screening visit.

16. Use of potent inhibitors of CYP3A4 within 2 weeks prior to baseline visit (see detailed list of drugs in protocol) (1 month for fluoxetine).

17. Use of amiodarone within 2 years prior to screening visit.

18. Pregnancy or breastfeeding.

19. Subjects with a clinically significant or unstable medical or surgical condition that would preclude safe and complete study participation, as determined by medical history, physical examinations, ECG, laboratory tests or chest X-ray. Such conditions may include:

• A cardiovascular or pulmonary disorder that cannot be well-controlled by standard treatment permitted by the study protocol.
• A gastrointestinal disorder that may affect the absorption of study medication.
• Renal, metabolic, endocrinological or hematological diseases.
• Any form of chronic liver disease, including known non-alcoholic steatohepatitis.
• A ≥2xULN serum elevation of either of the following at screening: ALT, AST or direct bilirubin.
• A QTc interval (obtained from either two ECG recordings at screening or from the mean value calculated from three measurements at baseline visit) which is ≥450msec.
• A family history of Long-QT syndrome.
• A history of drug and/or alcohol abuse.
• Major psychiatric disorder.
• A history of a convulsive disorder.
• Known hypersensitivity to either of the following: mannitol, meglumine or sodium stearyl fumarate.
• Known hypersensitivity that would preclude administration of laquinimod.

20. The subject's inability to give informed consent, or to complete the study, or if the subject is considered by the investigator to be, for any reason, an unsuitable candidate for this study.

21. A known history of sensitivity to Gadolinium.

22. Inability to successfully undergo MRI scanning.

23. A known history of hypersensitivity to natural or recombinant interferon beta, human albumin, or any other component of the formulation of Avonex®.

24. Subjects who suffer from any form of progressive MS

25. Any condition which the investigator feels may interfere with participation in the study

26. Subjects with a clinically significant or unstable medical or surgical condition that would preclude safe and complete study participation

27. Subjects who received any investigational medication, immunosuppressives or cytotoxic agents within 6 months prior to screening

28. Previous treatment with immunomodulators within two months prior to screening

29. Pregnancy or breastfeeding

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Teva Medical Expert, M.D.

Role: STUDY_DIRECTOR

Teva Branded Pharmaceutical Products R&D, Inc.

Locations

Teva Investigational Site 1267

Birmingham, Alabama, United States

Teva Investigational Site 1237

Phoenix, Arizona, United States

Teva Investigational Site 1252

Phoenix, Arizona, United States

Teva Investigational Site 1279

Phoenix, Arizona, United States

Teva Investigational Site 1276

Tucson, Arizona, United States

Teva Investigational Site 1272

Pasadena, California, United States

Teva Investigational Site 1238

Sacramento, California, United States

Teva Investigational Site 1280

Aurora, Colorado, United States

Teva Investigational Site 1255

Orlando, Florida, United States

Teva Investigational Site 1282

Sarasota, Florida, United States

Teva Investigational Site 1275

Atlanta, Georgia, United States

Teva Investigational Site 1250

Peoria, Illinois, United States

Teva Investigational Site 1260

Indianapolis, Indiana, United States

Teva Investigational Site 1268

Lenexa, Kansas, United States

Teva Investigational Site 1277

New Orleans, Louisiana, United States

Teva Investigational Site 1263

Shreveport, Louisiana, United States

Teva Investigational Site 1269

Baltimore, Maryland, United States

Teva Investigational Site 1274

Grand Rapids, Michigan, United States

Teva Investigational Site 1239

Lebanon, New Hampshire, United States

Teva Investigational Site 1265

Teaneck, New Jersey, United States

Teva Investigational Site 1273

Albany, New York, United States

Teva Investigational Site 1264

Amherst, New York, United States

Teva Investigational Site 1283

Cedarhurst, New York, United States

Teva Investigational Site 1249

Raleigh, North Carolina, United States

Teva Investigational Site 1262

Winston-Salem, North Carolina, United States

Teva Investigational Site 1261

Akron, Ohio, United States

Teva Investigational Site 1241

Canton, Ohio, United States

Teva Investigational Site 1245

Cleveland, Ohio, United States

Teva Investigational Site 1247

Columbus, Ohio, United States

Teva Investigational Site 1244

Portland, Oregon, United States

Teva Investigational Site 1258

Philadelphia, Pennsylvania, United States

Teva Investigational Site 1281

Nashville, Tennessee, United States

Teva Investigational Site 1284

San Antonio, Texas, United States

Teva Investigational Site 1248

Richmond, Virginia, United States

Teva Investigational Site 1270

Roanoke, Virginia, United States

Teva Investigational Site 1253

Tacoma, Washington, United States

Teva Investigational Site 5914

Pleven, , Bulgaria

Teva Investigational Site 5915

Pleven, , Bulgaria

Teva Investigational Site 5917

Plovdiv, , Bulgaria

Teva Investigational Site 4212

Rousse, , Bulgaria

Teva Investigational Site 5916

Shumen, , Bulgaria

Teva Investigational Site 5920

Sofia, , Bulgaria

Teva Investigational Site 5907

Sofia, , Bulgaria

Teva Investigational Site 5910

Sofia, , Bulgaria

Teva Investigational Site 5909

Sofia, , Bulgaria

Teva Investigational Site 5919

Sofia, , Bulgaria

Teva Investigational Site 5906

Sofia, , Bulgaria

Teva Investigational Site 5908

Sofia, , Bulgaria

Teva Investigational Site 5911

Sofia, , Bulgaria

Teva Investigational Site 5912

Sofia, , Bulgaria

Teva Investigational Site 5918

Stara Zagora, , Bulgaria

Teva Investigational Site 5913

Varna, , Bulgaria

Teva Investigational Site 4211

Veliko Tarnovo, , Bulgaria

Teva Investigational Site 6003

Osijek, , Croatia

Teva Investigational Site 6004

Split, , Croatia

Teva Investigational Site 6005

Varaždin, , Croatia

Teva Investigational Site 6001

Zagreb, , Croatia

Teva Investigational Site 6002

Zagreb, , Croatia

Teva Investigational Site 6006

Zagreb, , Croatia

Teva Investigational Site 5422

Brno, , Czechia

Teva Investigational Site 5419

Olomouc, , Czechia

Teva Investigational Site 5418

Prague, , Czechia

Teva Investigational Site 5420

Praha 5- Motol, , Czechia

Teva Investigational Site 5421

Teplice, , Czechia

Teva Investigational Site 5508

Kohtla-Järve, , Estonia

Teva Investigational Site 5507

Tallinn, , Estonia

Teva Investigational Site 5509

Tartu, , Estonia

Teva Investigational Site 8102

Tbilisi, , Georgia

Teva Investigational Site 8104

Tbilisi, , Georgia

Teva Investigational Site 8103

Tbilisi, , Georgia

Teva Investigational Site 6701

Bayreuth, , Germany

Teva Investigational Site 6703

Berlin, , Germany

Teva Investigational Site 6402

Berlin, , Germany

Teva Investigational Site 6700

Berlin, , Germany

Teva Investigational Site 6702

Dresden, , Germany

Teva Investigational Site 6401

Hanover, , Germany

Teva Investigational Site 6403

Münster, , Germany

Teva Investigational Site 6400

Ulm, , Germany

Teva Investigational Site 8043

Haifa, , Israel

Teva Investigational Site 8041

Jerusalem, , Israel

Teva Investigational Site 8040

Ramat Gan, , Israel

Teva Investigational Site 8042

Ramat Gan, , Israel

Teva Investigational Site 3056

Bologna, , Italy

Teva Investigational Site 3062

Catania, , Italy

Teva Investigational Site 3053

Cefalù, , Italy

Teva Investigational Site 3054

Chieti, , Italy

Teva Investigational Site 3061

Empoli, , Italy

Teva Investigational Site 3049

Florence, , Italy

Teva Investigational Site 3055

Napoli, , Italy

Teva Investigational Site 3048

Rome, , Italy

Teva Investigational Site 3052

Rome, , Italy

Teva Investigational Site 3050

Rome, , Italy

Teva Investigational Site 3060

Rome, , Italy

Teva Investigational Site 3051

Torino, , Italy

Teva Investigational Site 5708

Kaunas, , Lithuania

Teva Investigational Site 5707

Šiauliai, , Lithuania

Teva Investigational Site 6502

Bitola, , North Macedonia

Teva Investigational Site 6500

Skopje, , North Macedonia

Teva Investigational Site 6501

Skopje, , North Macedonia

Teva Investigational Site 5337

Bialystok, , Poland

Teva Investigational Site 5329

Gdansk, , Poland

Teva Investigational Site 5338

Gdansk, , Poland

Teva Investigational Site 4213

Gmina Końskie, , Poland

Teva Investigational Site 6602

Gorzów Wielkopolski, , Poland

Teva Investigational Site 5333

Grodzisk Mazowiecki, , Poland

Teva Investigational Site 5339

Katowice, , Poland

Teva Investigational Site 5334

Katowice, , Poland

Teva Investigational Site 6603

Kielce, , Poland

Teva Investigational Site 5332

Kościerzyna, , Poland

Teva Investigational Site 5345

Krakow, , Poland

Teva Investigational Site 5328

Lodz, , Poland

Teva Investigational Site 5330

Olsztyn, , Poland

Teva Investigational Site 5331

Szczecin, , Poland

Teva Investigational Site 5340

Warsaw, , Poland

Teva Investigational Site 5341

Warsaw, , Poland

Teva Investigational Site 5336

Warsaw, , Poland

Teva Investigational Site 5335

Wroclaw, , Poland

Teva Investigational Site 1243

Guaynabo, , Puerto Rico

Teva Investigational Site 5218

Bucharest, , Romania

Teva Investigational Site 5214

Bucharest, , Romania

Teva Investigational Site 5213

Bucharest, , Romania

Teva Investigational Site 5215

Cluj-Napoca, , Romania

Teva Investigational Site 5217

Constanța, , Romania

Teva Investigational Site 8209

Craiova, , Romania

Teva Investigational Site 5216

Iași, , Romania

Teva Investigational Site 5219

Sibiu, , Romania

Teva Investigational Site 5043

Barnaul, , Russia

Teva Investigational Site 5033

Moscow, , Russia

Teva Investigational Site 5032

Moscow, , Russia

Teva Investigational Site 5041

Moscow, , Russia

Teva Investigational Site 5038

Novosibirsk, , Russia

Teva Investigational Site 5042

Novosibirsk, , Russia

Teva Investigational Site 5036

Saint Petersburg, , Russia

Teva Investigational Site 5035

Saint Petersburg, , Russia

Teva Investigational Site 5034

Saint Petersburg, , Russia

Teva Investigational Site 5037

Samara, , Russia

Teva Investigational Site 5044

Ufa, , Russia

Teva Investigational Site 6200

Bratislava, , Slovakia

Teva Investigational Site 6201

Bratislava, , Slovakia

Teva Investigational Site 6202

Nitra, , Slovakia

Teva Investigational Site 6203

Žilina, , Slovakia

Teva Investigational Site 9007

Bloemfontein, , South Africa

Teva Investigational Site 9001

Cape Town, , South Africa

Teva Investigational Site 9004

Johannesburg, , South Africa

Teva Investigational Site 9003

Johannesburg, , South Africa

Teva Investigational Site 9008

Pietermaritzburg, , South Africa

Teva Investigational Site 9005

Pretoria, , South Africa

Teva Investigational Site 9006

Rosebank, , South Africa

Teva Investigational Site 3147

Barcelona, , Spain

Teva Investigational Site 3154

Figueres-Girona, , Spain

Teva Investigational Site 3149

L'Hospitalet de Llobregat, , Spain

Teva Investigational Site 3152

Madrid, , Spain

Teva Investigational Site 3151

Málaga, , Spain

Teva Investigational Site 3148

Seville, , Spain

Teva Investigational Site 3153

Tortosa-Tarragona, , Spain

Teva Investigational Site 6503

Chernihiv, , Ukraine

Teva Investigational Site 5823

Chernivtsi, , Ukraine

Teva Investigational Site 5811

Dnipropetrovsk, , Ukraine

Teva Investigational Site 5812

Donetsk, , Ukraine

Teva Investigational Site 5814

Ivano-Frankivsk, , Ukraine

Teva Investigational Site 5817

Kharkiv, , Ukraine

Teva Investigational Site 5818

Kharkiv, , Ukraine

Teva Investigational Site 5815

Kharkiv, , Ukraine

Teva Investigational Site 5822

Kyiv, , Ukraine

Teva Investigational Site 5809

Lviv, , Ukraine

Teva Investigational Site 5820

Odesa, , Ukraine

Teva Investigational Site 5821

Poltava, , Ukraine

Teva Investigational Site 5810

Vinnytsia, , Ukraine

Teva Investigational Site 5819

Zaporizhzhya, , Ukraine

Teva Investigational Site 5816

Zaporizhzhya, , Ukraine

Countries

United States; Bulgaria; Croatia; Czechia; Estonia; Georgia; Germany; Israel; Italy; Lithuania; North Macedonia; Poland; Puerto Rico; Romania; Russia; Slovakia; South Africa; Spain; Ukraine

References

Falet JR, Durso-Finley J, Nichyporuk B, Schroeter J, Bovis F, Sormani MP, Precup D, Arbel T, Arnold DL. Estimating individual treatment effect on disability progression in multiple sclerosis using deep learning. Nat Commun. 2022 Sep 26;13(1):5645. doi: 10.1038/s41467-022-33269-x.

Reference Type: DERIVED

PMID: 36163349 (View on PubMed)

Kolb-Sobieraj C, Gupta S, Weinstock-Guttman B. Laquinimod therapy in multiple sclerosis: a comprehensive review. Neurol Ther. 2014 May 6;3(1):29-39. doi: 10.1007/s40120-014-0017-6. eCollection 2014 Jun.

Reference Type: DERIVED

PMID: 26000222 (View on PubMed)

Other Identifiers

2007-005450-23

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

MS-LAQ-302

Identifier Type: -

Identifier Source: org_study_id